Logo-apb
Adv Pharm Bull. 2021;11(4): 684-692.
doi: 10.34172/apb.2021.077
PMID: 34888215
PMCID: PMC8642808
Scopus ID: 85117359628
  Abstract View: 1225
  PDF Download: 369
  Full Text View: 243

Research Article

Dual Antibiotic and Diffusible Signal Factor Combination Nanoliposomes for Combating Staphylococcus epidermidis Biofilm

Golara Gerayelou 1 ORCID logo, Bahman Khameneh 2 ORCID logo, Bizhan Malaekeh-Nikouei 3, Asma Mahmoudi 3, Bibi Sedigheh Fazly Bazzaz 1,4* ORCID logo

1 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
2 Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
3 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
4 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
*Corresponding Author: *Corresponding Author: Bibi Sedigheh Fazly Bazzaz, Tel: +98-51-31801130, Fax: +98-51-38823251, E-mail: , Email: Fazlis@mums.ac.ir

Abstract

Purpose: Microbial biofilms are one of the main causes of persistent human infections. Encapsulation of an antibiotic and a biofilm dispersal agent within a nano-carrier has been recognized as a novel approach to combat the problem of biofilm-related infections. Here, we develop the nanoliposomal formulation for delivery of vancomycin in combination with cis-2- decenoic acid (C2DA), to Staphylococcus epidermidis biofilm. The effects of the formulations were studied at two stages: biofilm growth inhabitation and biofilm eradication.

Methods: Liposomal formulations were prepared by the solvent evaporation dehydration-rehydration method and were evaluated for size, zeta potential, and encapsulation efficacy. The ability of different agents in free and encapsulated forms were assessed to evaluate the anti-biofilm activities.

Results: Vancomycin and C2DA were successfully co-encapsulated in the same nanoliposome (liposomal combination). The zeta potential values of the liposomal formulations of vancomycin, C2DA, and the liposomal combination were 37.2, 40.2, 51.5 mV, and the mean sizes of these liposomal formulations were 167.8±1.5, 215.5±8.8, 235.5±0.01, respectively. Encapsulation efficacy of C2DA was 65% and about 40% for vancomycin. The results indicated that liposomal combination exerted strong anti-biofilm activities, slightly exceeding those observed by the free form of a combination of vancomycin and C2DA, but higher than either agent used alone in their free forms. The anti-biofilm activity of formulations followed concentration and time-dependent manner.

Conclusion: The combination of vancomycin and C2DA could inhibit biofilm formation. Employing the liposomal combination is a considerable method to remove bacterial biofilm.




First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1226

Your browser does not support the canvas element.


PDF Download: 369

Your browser does not support the canvas element.


Full Text View: 243

Your browser does not support the canvas element.

Submitted: 27 May 2020
Revision: 18 Sep 2020
Accepted: 14 Oct 2020
ePublished: 14 Oct 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)